The latest price target for Medexus Pharma (OTCQX:MEDXF) was reported by Raymond James on September 20, 2022. The analyst firm set a price target for $2.00 expecting MEDXF to fall to within 12 months (a possible NaN% downside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for Medexus Pharma (OTCQX:MEDXF) was provided by Raymond James, and Medexus Pharma downgraded their market perform rating.

There is no last upgrade for Medexus Pharma

The last downgrade for Medexus Pharmaceuticals Inc happened on September 20, 2022 when Raymond James changed their price target from $4.5 to $2 for Medexus Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Medexus Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Medexus Pharma was filed on September 20, 2022 so you should expect the next rating to be made available sometime around September 20, 2023.

While ratings are subjective and will change, the latest Medexus Pharma (MEDXF) rating was a downgraded with a price target of $4.50 to $2.00. The current price Medexus Pharma (MEDXF) is trading at is $undefined, which is out of the analyst’s predicted range.